| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.4284 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.4369 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.4457 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.4507 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.4531 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.4570 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.4752 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5042 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5276 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5335 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5343 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5612 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5688 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5756 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5834 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5835 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5879 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5908 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.5960 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6059 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6101 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6135 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6172 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6343 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6360 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6370 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6393 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6407 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6427 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6560 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6620 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6637 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6732 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6770 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6781 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6788 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6844 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6885 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6928 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.6941 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7076 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7165 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7219 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7381 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7383 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7385 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7455 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7456 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7475 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7500 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7531 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7541 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7576 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7613 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7621 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7675 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7732 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.7801 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8029 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8030 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8038 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8049 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8062 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8164 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8234 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8262 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8312 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8322 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8367 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8383 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8395 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8437 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8474 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8593 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8662 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8749 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8752 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8810 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8824 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8845 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8923 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8938 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.8980 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.9205 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.9343 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.9403 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.9596 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.9599 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.9605 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.9751 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.9875 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.9885 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 0.9906 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0000 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0008 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0094 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0128 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0222 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0227 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0233 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0255 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0271 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0284 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0376 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0399 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0403 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0424 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0472 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0477 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0535 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0623 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0715 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0745 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0850 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0918 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0989 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.0993 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1051 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1060 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1190 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1191 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1195 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1211 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1350 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1404 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1714 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1839 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1847 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1866 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.1925 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.2118 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.2288 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.2353 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.2395 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.2455 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.2464 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.2478 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.2751 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.2959 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.3151 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.3240 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.3591 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.3599 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.3606 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.3754 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.3912 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.4061 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.4071 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.4290 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.4384 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.4556 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.4618 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.4718 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.4779 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.5176 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.5425 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.5692 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.5814 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.6081 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.6147 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.6848 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.7419 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.7507 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.8138 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.8836 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.9189 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 1.9218 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.0029 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.0469 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.0525 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.0572 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.1874 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.1966 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.2334 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.2590 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.3151 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.3231 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.3369 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.3869 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.4211 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.7309 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.7409 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 2.9369 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 3.0337 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 3.1358 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 3.1521 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | oleoyl ethanolamide | 3.2423 | scaled units | Low-Dose | -0.5HR |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|